Clinical Utility of the Neutrophil-to-Bilirubin Ratio in the Detection of Disease Activity in Ulcerative Colitis

References

• Alatab S, Sepanlou SG, Ikuta K; Collaborators, G.B.D.I.B.D. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5:17–30. doi:10.1016/S2468-1253(19)30333-4
   PubMed Web of Science ®Google Scholar
• Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720–727. doi:10.1038/nrgastro.2015.150
   PubMed Web of Science ®Google Scholar
• Park KT, Ehrlich OG, Allen JI, et al. The cost of inflammatory bowel disease: an initiative from the crohn’s & colitis foundation. Inflamm Bowel Dis. 2020;26:1–10. doi:10.1093/ibd/izz104
   PubMed Web of Science ®Google Scholar
• Rajbhandari R, Blakemore S, Gupta N, et al. Crohn’s disease in low and lower-middle income countries: a scoping review. World J Gastroenterol. 2020;26:6891–6908. doi:10.3748/wjg.v26.i43.6891
   PubMed Web of Science ®Google Scholar
• Soubieres AA, Poullis A. Emerging biomarkers for the diagnosis and monitoring of inflammatory bowel diseases. Inflamm Bowel Dis. 2016;22:2016–2022. doi:10.1097/MIB.0000000000000836
   PubMedGoogle Scholar
• Sunakawa H, Yoda Y, Takahashi M, et al. A prospective study on the risk of transmission due to droplets and aerosols during an endoscopic procedure and the usefulness of extraoral suction devices. Dig Endosc. 2022;2022:1.
   Google Scholar
• Chebli JMF, Queiroz NSF, Damião AOMC, et al. How to manage inflammatory bowel disease during the COVID-19 pandemic: a guide for the practicing clinician. World J Gastroenterol. 2021;27:1022–1042. doi:10.3748/wjg.v27.i11.1022
   PubMed Web of Science ®Google Scholar
• Caire MT, Strauss AT, Kumar A, Brady P. Emerging biomarkers for the diagnosis and monitoring of inflammatory bowel diseases. Inflamm Bowel Dis. 2016;22:E46. doi:10.1097/MIB.0000000000000973
   PubMedGoogle Scholar
• Caviglia GP, Ribaldone DG, Rosso C, et al. Fecal calprotectin: beyond intestinal organic diseases. Panminerva Med. 2018;60:29–34. doi:10.23736/S0031-0808.18.03405-5
   PubMed Web of Science ®Google Scholar
• Zhou Z, Zhang Y, Yang X, et al. Clinical significance of novel neutrophil-based biomarkers in the diagnosis and prediction of response to infliximab therapy in Crohn’s disease. Front Immunol. 2022;13:865968. doi:10.3389/fimmu.2022.865968
   PubMed Web of Science ®Google Scholar
• Zhou Z, Zhang Y, Pan Y, et al. A novel neutrophil-based biomarker to monitor disease activity and predict response to infliximab therapy in patients with ulcerative colitis. Front Med. 2022;9:872831. doi:10.3389/fmed.2022.872831
   Web of Science ®Google Scholar
• Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753. doi:10.1136/gut.2005.082909
   PubMed Web of Science ®Google Scholar
• Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–1666. doi:10.1002/ibd.20520
   PubMed Web of Science ®Google Scholar
• D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–786. doi:10.1053/j.gastro.2006.12.038
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–1629. doi:10.1056/NEJM198712243172603
   PubMed Web of Science ®Google Scholar
• Simundic AM. Measures of diagnostic accuracy: basic definitions. EJIFCC. 2009;19:203–211.
   PubMedGoogle Scholar
• Su Q, Li X, Mo W, Yang Z. Low serum bilirubin, albumin, and uric acid levels in patients with Crohn’s disease. Medicine. 2019;98:e15664. doi:10.1097/MD.0000000000015664
   PubMed Web of Science ®Google Scholar
• Zhao X, Li L, Li X, et al. The relationship between serum bilirubin and inflammatory bowel disease. Mediators Inflamm. 2019;2019:5256460. doi:10.1155/2019/5256460
   PubMed Web of Science ®Google Scholar
• Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61:1619–1635. doi:10.1136/gutjnl-2012-302830
   PubMed Web of Science ®Google Scholar
• Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13:144–164. doi:10.1093/ecco-jcc/jjy113
   PubMed Web of Science ®Google Scholar
• Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451–459. doi:10.1053/j.gastro.2003.11.010
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004;126:402–413. doi:10.1053/j.gastro.2003.11.014
   PubMed Web of Science ®Google Scholar
• Naganuma M, Aoyama N, Suzuki Y, et al. Twice-daily budesonide 2-mg foam induces complete mucosal healing in patients with distal ulcerative colitis. J Crohns Colitis. 2016;10:828–836. doi:10.1093/ecco-jcc/jjv208
   PubMed Web of Science ®Google Scholar
• Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology. 2015;149:1275–1285 e1272. doi:10.1053/j.gastro.2015.07.003
   PubMed Web of Science ®Google Scholar
• Torun S, Tunc BD, Suvak B, et al. Assessment of neutrophil-lymphocyte ratio in ulcerative colitis: a promising marker in predicting disease severity. Clin Res Hepatol Gastroenterol. 2012;36:491–497. doi:10.1016/j.clinre.2012.06.004
   PubMed Web of Science ®Google Scholar
• Akpinar MY, Ozin YO, Kaplan M, et al. Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio predict mucosal disease severity in ulcerative colitis. J Med Biochem. 2018;37:155–162. doi:10.1515/jomb-2017-0050
   PubMed Web of Science ®Google Scholar
• Cherfane CE, Gessel L, Cirillo D, Zimmerman MB, Polyak S. Monocytosis and a low lymphocyte to monocyte ratio are effective biomarkers of ulcerative colitis disease activity. Inflamm Bowel Dis. 2015;21:1769–1775. doi:10.1097/MIB.0000000000000427
   PubMed Web of Science ®Google Scholar
• Zhou GX, Liu ZJ. Potential roles of neutrophils in regulating intestinal mucosal inflammation of inflammatory bowel disease. J Dig Dis. 2017;18:495–503. doi:10.1111/1751-2980.12540
   PubMed Web of Science ®Google Scholar
• Magro F, Langner C, Driessen A, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013;7:827–851. doi:10.1016/j.crohns.2013.06.001
   PubMed Web of Science ®Google Scholar
• He J, Jiang G, Li X, et al. Bilirubin represents a negative regulator of ILC2 in allergic airway inflammation. Mucosal Immunol. 2022;15:314–326. doi:10.1038/s41385-021-00460-0
   PubMed Web of Science ®Google Scholar
• Liu Y, Li P, Lu J, et al. Bilirubin possesses powerful immunomodulatory activity and suppresses experimental autoimmune encephalomyelitis. J Immunol. 2008;181:1887–1897. doi:10.4049/jimmunol.181.3.1887
   PubMed Web of Science ®Google Scholar
• Zucker SD, Vogel ME, Kindel TL, et al. Bilirubin prevents acute DSS-induced colitis by inhibiting leukocyte infiltration and suppressing upregulation of inducible nitric oxide synthase. Am J Physiol Gastrointest Liver Physiol. 2015;309:G841–854. doi:10.1152/ajpgi.00149.2014
   PubMed Web of Science ®Google Scholar
• Zhao C, Huang H, Pan Q, et al. Unconjugated Bilirubin attenuates DSS-Induced colitis potentially via enhancement of bilirubin reabsorption. Front Pharmacol. 2021;12:654808. doi:10.3389/fphar.2021.654808
   PubMed Web of Science ®Google Scholar
• Longhi MS, Vuerich M, Kalbasi A, et al. Bilirubin suppresses Th17 immunity in colitis by upregulating CD39. JCI Insight. 2017;2. doi:10.1172/jci.insight.92791
   PubMed Web of Science ®Google Scholar
• de Vries HS, Te Morsche RH, Jenniskens K, Peters WH, de Jong DJ. A functional polymorphism in UGT1A1 related to hyperbilirubinemia is associated with a decreased risk for Crohn’s disease. J Crohns Colitis. 2012;6:597–602. doi:10.1016/j.crohns.2011.11.010
   PubMed Web of Science ®Google Scholar
• Lenicek M, Ďuricová D, Hradsky O, et al. The relationship between serum bilirubin and Crohn’s disease. Inflamm Bowel Dis. 2014;20:481–487. doi:10.1097/01.MIB.0000440817.84251.98
   PubMed Web of Science ®Google Scholar
• Rogler G, Vavricka S, Schoepfer A, Lakatos PL. Mucosal healing and deep remission: what does it mean? World J Gastroenterol. 2013;19:7552–7560. doi:10.3748/wjg.v19.i43.7552
   PubMed Web of Science ®Google Scholar
• Froslie KF, Jahnsen J, Moum BA, Vatn MH, Group I. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412–422. doi:10.1053/j.gastro.2007.05.051
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9:483–489 e483. doi:10.1016/j.cgh.2010.12.028
   PubMed Web of Science ®Google Scholar
• Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53:1813–1816. doi:10.1136/gut.2003.038505
   PubMed Web of Science ®Google Scholar
• Navaneethan U, Parasa S, Venkatesh PG, Trikudanathan G, Shen B. Prevalence and risk factors for colonic perforation during colonoscopy in hospitalized inflammatory bowel disease patients. J Crohns Colitis. 2011;5:189–195. doi:10.1016/j.crohns.2010.12.005
   PubMed Web of Science ®Google Scholar
• Buisson A, Gonzalez F, Poullenot F, et al. Comparative acceptability and perceived clinical utility of monitoring tools: a nationwide survey of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:1425–1433. doi:10.1097/MIB.0000000000001140
   PubMed Web of Science ®Google Scholar